Inventor · disambiguated record
Yann Echelard
Also filed as: ECHELARD YANN · ECHELARD YANN PAUL GUY RÉGIS
3 granted patents·32 pending applications·67 citations·filing 1998–2025
74Inventor score
Files withFLAGSHIP PIONEERING INNOVATIONS VII LLC5FLAGSHIP PIONEERING INNOVATIONS VI LLC4GTC BIOTHERAPEUTICS INC4GENZYME TRANSGENICS CORP3STROME SCOTT E3
Top patents by PatentIndex Score
35 records- 0170US6545198B1Transgenically produced prolactinGENZYME TRANSGENICS CORP·Filed 2000·Granted Apr 8, 2003·14 cites·11 claims
- 0266US2023203158A1Methods for modulating intestine cells or tissue functionFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2022·Application pending·0 cites
- 0365US6580017B1Methods of reconstructed goat embryo transferGENZYME TRANSGENICS CORP·Filed 1999·Granted Jun 17, 2003·28 cites·73 claims
- 0463US2025352638A1Coronavirus immunogen compositions and their usesFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2022·Application pending·0 cites
- 0562US2025353906A1Compositions and methods for targeted delivery of therapeutic agentsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2023·Application pending·0 cites
- 0657US2004226053A1Methods of producing a target molecule in a transgenic animal and purification of the target moleculeFiled 2004·Application pending·0 cites
- 0757US2004226052A1Methods of producing a target molecule in a transgenic animal and purification of the target moleculeFiled 2004·Application pending·0 cites
- 0856US2023227849A1Methods of identifying and characterizing anelloviruses and uses thereofFLAGSHIP PIONEERING INNOVATIONS V INC·Filed 2021·Application pending·0 cites
- 0956US2024009298A1Immunogenic compositions and uses thereofFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2021·Application pending·0 cites
- 1056US2025163151A1Methods for modulating intestine cells or tissue functionFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2025·Application pending·0 cites
- 1155US6210736B1Transgenically produced prolactinGENZYME TRANSGENICS CORP·Filed 1998·Granted Apr 3, 2001·25 cites·6 claims
- 1254US2004117863A1Transgenically produced fusion proteinsFiled 2003·Application pending·0 cites
- 1354US2023181722A1Coronavirus antigen compositions and their usesFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2021·Application pending·0 cites
- 1454US2023193311A1Immunogenic compositions and uses thereofFLAGSHIP PIONEERING INNOVATIONS VI LLC·Filed 2021·Application pending·0 cites
- 1553US2025320254A1Compositions and Methods for Modulating Circulating FactorsFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2023·Application pending·0 cites
- 1653US2025319115A1Compositions and Methods for Modulating CytokinesFLAGSHIP PIONEERING INNOVATIONS VII LLC·Filed 2023·Application pending·0 cites
- 1753US2006191025A1Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transferGTC BIOTHERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 1852US2005245444A1Method of using recombinant human antithrombin for neurocognitive disordersECHELARD YANN·Filed 2004·Application pending·0 cites
- 1951US2023203192A1Compositions and methods for producing human polyclonal antibodiesFLAGSHIP PIONEERING INC·Filed 2021·Application pending·0 cites
- 2051US2008004212A1Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombinGTC BIOTHERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2151US2006179500A1Methods and vectors for improving nucleic acid expressionGTC BIOTHERAPEUTICS INC·Filed 2006·Application pending·0 cites
- 2250US2012058047A9Method of using an anti-cd137 antibody as an agent for radioimmunotherapy or radioimmunodetectionSTROME SCOTT E·Filed 2010·Application pending·0 cites
- 2349US2006121004A1Methods of reducing the incidence of rejection in tissue transplantation through the use of recombinant human antithrombinECHELARD YANN·Filed 2004·Application pending·0 cites
- 2448US2006026695A1Transgenically produced fusion proteinsEDGE MICHAEL D·Filed 2005·Application pending·0 cites
- 2547US2008019905A9Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetectionSTROME SCOTT E·Filed 2005·Application pending·0 cites
- 2647US2005208000A1Compositions and methods for prevention of photoagingBERNSTEIN ERIC F·Filed 2005·Application pending·0 cites
- 2746US2012263663A1Compositions and methods for prevention of photoagingBERNSTEIN ERIC F·Filed 2012·Application pending·0 cites
- 2846US2006123500A1Methods of prescreening cells for nuclear transfer proceduresGTC BIOTHERAPEUTICS INC·Filed 2005·Application pending·0 cites
- 2945US2004148648A1Method and system for utilizing somatic cell nuclear transfer embryos as cell donors for additional nuclear transferFiled 2003·Application pending·0 cites
- 3045US2003005468A1Methods and vectors for improving nucleic acid expressionFiled 2002·Application pending·0 cites
- 3145US2004025193A1Method for the rapid selection of homozygous primary cell lines for the production of transgenic animals by somatic cell nuclear transferFiled 2003·Application pending·0 cites
- 3241US2003046716A1Transgenically produced platelet derived growth factorFiled 2001·Application pending·0 cites
- 3339US2006182744A1Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereofSTROME SCOTT E·Filed 2005·Application pending·0 cites
- 3438US2005193431A1Somatic cell lineFiled 2003·Application pending·0 cites
- 3536US2003177513A1Transgenic and cloned mammalsFiled 2003·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yann Echelard files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →